Literature DB >> 16324322

[Inhibitory effects of esophageal cancer related gene 2 on proliferation of human esophageal cancer cell EC9706].

Mei-ning Li1, Ge Huang, Li-ping Guo, Shih-hsin Lu.   

Abstract

OBJECTIVE: To investigate the inhibitory role of esophageal cancer related gene 2 (ECRG2) on proliferation of human esophageal cancer cell EC9706.
METHODS: Recombinant plasmid pcDNA3.1-ECRG2 with ECRG2 open reading frame was constructed. The cells were transfected with either pcDNA3.1 or pcDNA3.1-ECRG2 using Lipofectamin 2000. The expression of ECRG2 protein was examined by Dot Blot analysis. The effects of ECRG2 on cell proliferation and malignant was analyzed by colony formation assay. The variation of P53 and P21 were detected in EC9706 cells with or without expression of ECRG2.
RESULTS: The plasmid of pcDNA3.1-ECRG2 was successfully established. Colony formation activity of EC9706/pcDNA3.1-ECRG2 was 18% while that of the control cell was 55% in six well plate (P < 0.05). The activity of anchorage-independent proliferation of EC9706/pcDNA3.1-ECRG2 was lower than that of EC9706/pcDNA3.1 in soft agar. After transfected with pcDNA3.1-ECRG2, the expression of P53 and P21 were higher than control.
CONCLUSION: ECRG2 can reduced the abilities of proliferation and of anchorage-independent proliferation of EC9706 cells which is through p53 pathway possibility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16324322

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  2 in total

1.  ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA.

Authors:  Xin-Fang Hou; Lin-Ping Xu; Hai-Yan Song; Shuai Li; Chen Wu; Ju-Feng Wang
Journal:  World J Gastroenterol       Date:  2017-03-14       Impact factor: 5.742

2.  Effect of ECRG2 in combination with cisplatin on the proliferation and apoptosis of EC9706 cells.

Authors:  Hai-Yan Song; Xiao-Hui Deng; Xin-Fang Hou; Guo-Yan Yuan; Zhen-Dong Zhu; Ming-Xin Ren
Journal:  Exp Ther Med       Date:  2014-09-17       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.